Tuesday, May 31, 2016

 

 



Soy un nuevo usuario

Olvidé mi contraseña

Entrada usuarios

Lógica Matemáticas Astronomía y Astrofísica Física Química Ciencias de la Vida
Ciencias de la Tierra y Espacio Ciencias Agrarias Ciencias Médicas Ciencias Tecnológicas Antropología Demografía
Ciencias Económicas Geografía Historia Ciencias Jurídicas y Derecho Lingüística Pedagogía
Ciencia Política Psicología Artes y Letras Sociología Ética Filosofía
 

rss_1.0 Recursos de colección

ORBi Open Repository and Bibliography (253,116 recursos)
In may 2007, the ULg's Administrative Board (joined in June 2007 by the FUSAGx) decided to create an institutional repository and defined a strong institutional self-archiving policy to increase the visibility, accessibility and impact of the University's publications (Board's decision). This decision led to the official launch, in November 2008, of the ORBi platform including both the Academic Bibliography and the Institutional Repository of the Wallonia-Europe University Academy.

Human health sciences => Hematology

Mostrando recursos 601 - 620 de 973

601. Repeated beta irradiation for recurrent coronary in-stent restenosis. - Eeckhout, E [author]; Roguelov, C [author]; Berger, A [author]; Lyon, X [author]; Imsand, C [author]; Girod, G [author]; COUCKE, Philippe [author]
Vascular brachytherapy (VBT) is the only proven treatment option for patients with in-stent restenosis. In seven randomised trials with almost 1500 patients that evaluated {gamma} (five studies) and ß (two trials) irradiation, target vessel failure reduction ranged from 73% to 34% by VBT compared with conventional angioplasty.1 However, the reported restenosis rates with the active treatment still varied between 17% and 32%.1 We therefore postulated that repeat VBT is safe and efficacious for preventing refractory in-stent restenosis in high risk patients with failed VBT. METHODS Beginning in January 1999, VBT was applied for all patients with in-stent restenosis. VBT was systematically performed...

602. Préoperative hyperfractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective trial. - Coucke, Philippe [author]; Notter, M [author]; Matter, M [author]; Fasolini, F [author]; Calmes, J-M [author]; Schlumpf, R [author]; Matzinger, O [author]; Schwegler, N [author]; Do, H-P [author]; Stamm, B [author]; Bouzourene, H [author]
Abstract Background and purpose: We aim to report on local control in a phase II trial on preoperative hyperfractionated and accelerated radiotherapy schedule (HART) in locally advanced resectable rectal cancer (LARC). This fractionation schedule was designed to keep the overall treatment time (OTT) as short as possible. Patients and methods: This is a prospective trial on patients with UICC stages II and III rectal cancer. The patients were submitted to a total dose of 41.6 Gy, delivered in 2.5 weeks at 1.6 Gy per fraction twice a day with a 6-h interfraction interval. Surgery was performed within 1 week after the end of irradiation. Adjuvant chemotherapy...

603. Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): Is it a matter of days? - Coucke, Philippe; Notter, Markus; Matter, Maurice; Fasolini, Fabrizio; Calmes, Jean-Marie; Schlumpf, Rolph; Schwegler, N; Stamm, B; Phuoc Do, H; Bouzourene, H
We intend to analyse retrospectively whether the time interval ("gap duration" = GD) between preoperative radiotherapy and surgery in locally advanced rectal cancer (LARC) has an impact on overall survival (OS), cancer specific survival (CSS), disease free survival (DFS) and local control (LC). Two hundred seventy nine patients with LARC were entered in Trial 93-01 (hyperfractionated accelerated radiotherapy 41.6 Gy/26 Fx BID) shortly followed by surgery. From these 250 patients are fully assessable. The median GD of 5 days was used as a discriminator. The median follow-up for all patients was 39 months. GD > 5 days was a significant...

604. CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II - Voelter, V [author]; Zouhair, A [author]; Vuilleumier, H [author]; Matter, M [author]; Bouzourene, H [author]; Leyvraz [author]; Bauer, J [author]; COUCKE, Philippe [author]; Stupp, R [author]
Patients with rectal cancer are at high risk of disease recurrence despite neoadjuvant radiochemotherapy with 5-Fluorouracil (5FU), a
regimen that is now widely applied. In order to develop a regimen with increased antitumour activity, we previously established the
recommended dose of neoadjuvant CPT-11 (three times weekly 90 mgm 2) concomitant to hyperfractionated accelerated
radiotherapy (HART) followed by surgery within 1 week. Thirty-three patients (20 men) with a locally advanced adenocarcinoma of
the rectum were enrolled in this prospective phase II trial (1 cT2, 29 cT3, 3 cT4 and 21 cNþ). Median age was 60 years (range 43–
75 years). All...

605. Innovations technologiques en radiothérapie-oncologie - Coucke, Philippe [author]; Louis, Céline [author]; Bolle, Stéphanie [author]
InnovatIve technologIes In radIatIon oncology SUMMARY : At present, radiation oncology is again flourishing thanks to the development of highly accurate techniques as intensity modulated radiation therapy, stereotactic radiation therapy and hadrontherapy. These therapeutic modalities are made possible by the advent of image guided radiation therapy and respiratory gating that allows a better patient repositioning during the irradiation and between fractions. Nowadays, thanks to these recent technological advances, one can more easily conceive dose escalation, hypofractionation and combined treatment of radiation with sensitizing drugs and this together with a better protection of normal tissue aiming at, simultaneously, improved tumour control and better quality of life. This article describes these innovative technologies that, when integrated...

606. Simultaneous alteration of de novo and salvage pathway to the deoxynucleoside thriphosphate pool by (E)-2'-deoxy-(fluoromethylene)cytidine (FMDC) and zidovudine (AZT) results in increased radiosensitivity in vitro. - Coucke, Philippe; Cottin, Eliane; Laurent, A; Decosterd, A
Abstract To test whether a thymidine analog zidovudine (=AZT), is able to modify the radiosensitizing effects of (E)-2'-Deoxy-(fluoromethylene)cytidine (FMdC). A human colon cancer cell line Widr was exposed for 48 hours prior to irradiation to FMdC. Zidovudine was added at various concentrations immediately before irradiation. We measured cell survival and the effect of FMdC, AZT and FMdC + AZT on deoxynucleotide triphosphate pool. FMdC results in a significant increase of radiosensitivity. The enhancement ratios (ER =surviving fraction irradiated cells/surviving fraction drug treated and irradiated cells), obtained by FMdC or AZT alone are significantly increased by the combination of both compounds. Adding...

607. Risk adaptive treatment in Hodgkin's lympoma: reduction of radiation dose and irradiated volume - Coucke, Philippe; Barthelemy, Nicole; Hustinx, Roland; Fillet, Georges
Treatment–related late complications on nontarget normal tissues and appearance of secondary malignancies are well known side-effects induced by effective treatment regimens currently used in the curative approach of early and advanced Hodgkin’s lymphoma. Radiotherapy (RT) and chemotherapy (CT) can lead to these late complications. Efforts have been conducted to reduce the morbidity and mortality related to these treatments. In particular there has been a progressive shift from radiotherapy used as sole modality to chemotherapy as first line followed by consolidation radiotherapy. As the side-effects of radiotherapy are linked to dose, volume and interaction with chemotherapy, trials have been launched to assess the impact of modifying the characteristics of the radiation treatment. For early-stage Hodgkin’s lymphoma radiotherapy cannot be...

608. Risk adaptive treatment in Hodgkin's lympoma: reduction of radiation dose and irradiated volume - Coucke, Philippe; Barthelemy, Nicole; Hustinx, Roland; Fillet, Georges
Treatment–related late complications on nontarget normal tissues and appearance of secondary malignancies are well known side-effects induced by effective treatment regimens currently used in the curative approach of early and advanced Hodgkin’s lymphoma. Radiotherapy (RT) and chemotherapy (CT) can lead to these late complications. Efforts have been conducted to reduce the morbidity and mortality related to these treatments. In particular there has been a progressive shift from radiotherapy used as sole modality to chemotherapy as first line followed by consolidation radiotherapy. As the side-effects of radiotherapy are linked to dose, volume and interaction with chemotherapy, trials have been launched to assess the impact of modifying the characteristics of the radiation treatment. For early-stage Hodgkin’s lymphoma radiotherapy cannot be...

609. Carcinome intracanalaire (in situ) du sein : pouvons-nous raisonnablement éviter les radiothérapie pour certaines patientes opérées? - Coucke, Philippe; Barthelemy, Nicole
Peer reviewed

610. Is an evidence-based approach unrealistic in NSCLC? - Coucke, Philippe [author]; Barthelemy, Nicole [author]; Bosquee, Léon [author]; Van Meerbeeck [author]
Summary Non-small cell lung cancer (NSCLC) is a heterogeneous tumour. A wide variety of treatment options is currently available. Surgery remains the mainstay of curative treatment and an operative approach will be selected in function of disease stage, tumour resectability and performance status of the patient. Adjuvant chemotherapy is considered standard at least for stage II and III disease. In stage III disease, resectability should be decided in function of the cytological/histological confirmation of N2 disease. If N2-disease cannot be highlighted at work-up, the patients are submitted to surgery followed by adjuvant chemotherapy. If patients are staged pN0-pN1 after surgery, ostoperative radiotherapy should not be given....

611. Les standards de radiothérapie en gynécologie: cancer du sein (Gunaikeia) - Coucke, Philippe [author]
Aan de hand van de literatuur willen we een overzicht geven van wat als een standaardbehandeling kan worden beschouwd bij borstkanker. We hebben het vooral over de plaats van radiotherapie bij ductaal carcinoom en over de onmogelijkheid om momenteel een subgroep van patiënten te definiëren bij wie zou kunnen worden afgezien van bestraling na de heelkundige ingreep. Voor infiltrerende borstkanker die met conservatieve borstklierchirurgie wordt behandeld, nemen we de recente publicaties door over het belang van een boost op het operatieveld na bestraling van de borstklier. We bespreken ook het gunstige effect op de overleving van radiotherapie na mastectomie bij patiënten met klierinvasie, ongeacht het aantal positieve klieren. Verder behandelen we enkele...

612. How much is enough? - Coucke, Philippe [author]
Le traitement conservateur est une constante dans l’approche oncologique. Des efforts ont été développés afin de conserver au maximum l’intégrité de la fonction et/ou de l’image corporelle. Ce souci de sauvegarde se traduit par des approches thérapeutiques non mutilantes: un exemple typique est le changement de paradigme thérapeutique au moment de l’introduction de la chirurgie conservatrice de la glande mammaire en lieu et place de la mastectomie. Ce concept de chirurgie non radicale a été possible grâce à l’association avec la radiothérapie externe postopératoire. Des essais randomisés ont permis de valider le concept et de démontrer que le risque de rechute loco-régionale et ultérieurement la survie ne sont...

613. Les standards de radiothérapie en gynécologie : cancer du col utérin - Coucke, Philippe
Sur base de la littérature, nous voulons faire le point sur ce qui peut être considéré comme une approche standard pour le traitement du cancer du col utérin. Nous évoquerons en particulier les questions suivantes: traitement adjuvant après chirurgie pour les stades précoces, la chirurgie adjuvante après une première chimio-radiothérapie pour les stades avancés, la place de la chimiothérapie néo-adjuvante ainsi que d’autres modalités destinées à augmenter l’effet anti-tumoral des radiations ionisantes. Introduction La prise en charge des cancers dans la sphère gynécologique nécessite une concertation multidisciplinaire ab initio. En effet, différentes approches peuvent être envisagées, et il est primordial de définir avant tout acte thérapeutique la séquence et la synchronisation des différentes modalités...

614. Les standards de radiothérapie en gynécologie: cancer du sein - Coucke, Philippe
Introduction Les cancers gynécologiques, et en particulier les cancers mammaires, bénéficient d’une prise en charge multidisciplinaire et concertée. Dans le contexte multidisciplinaire, la radiothérapie externe tient un rôle important visant à consolider en premier lieu le contrôle local mais également à améliorer la survie. Par une revue de la littérature nous voulons décrire les «standards» établis, en particulier pour la composante radiothérapie de cette approche multidisciplinaire. Cette recherche de «standards» permet par ailleurs d’évoquer un certain nombre de questions restées à ce jour ouvertes et qui méritent d’être évaluées de façon prospective et randomisée.Conclusions La radiothérapie externe améliore significativement le contrôle local, à tel point qu’on ne peut s’abstenir de la proposer à toute patiente après...

615. Selective defect of anti-pneumococcal IgG in a patient with persistent polyclonal B cell lymphocytosis. - Hafraoui, Kaoutar; Moutschen, Michel; Smet, Julie; Mascart, Francoise; Schaaf-Lafontaine, Nicole; Fillet, Georges
BACKGROUND: Persistent polyclonal B cell lymphocytosis (PPBL) is a rare condition characterized by increased IgM and large excess of B cells with an IgD(+) CD27(+) phenotype. In normal individuals, these cells play a central role in the defense against pneumococcal infection. So far, few studies have characterized humoral immune responses in PPBL patients. We therefore measured IgG directed against S. pneumoniae antigens in a 51 yr-old woman with PPBL before and after vaccination with a pneumococcal 23-valent polysaccharide vaccine. METHODS: Antibodies against pneumococcal antigens were measured first with an overall immunoassay using microplates coated with the 23-valent pneumococcal vaccine. A...

616. Cancers secondaires après allogreffe de cellules souches hématopoïétiques - Hafraoui, Kaoutar; Beguin, Yves; Baron, Frédéric
Cet article de revue cherche à répondre à quatre questions : 1) quelle ets l'incidence de cancer secondaire après allogreffe de cellules souches hématopoïétiques ? 2) quels sont les cancers plus fréquents chez les survivants d'une allogreffe par rapport à la population générale ? 3) quels sont les facteurs de risque de la survenue des cancers secondaires ? et 4) comment peut-on prévenir l'apparition des cancers secondaires ?

617. Reconstitution du système immunitaire après allogreffe de cellules souches hématopoïétiques - Castermans, Emilie; Hannon, Muriel; Drion, Pierre; Geenen, Vincent; Beguin, Yves; Baron, Frédéric
L'allogreffe de cellules souches hématopoïétiques (alloHCT) est le traitement de référence pour de nombreux patients atteints d'un cancer hématologique. Son efficacité dépend pour une large part de la destruction des cellules tumorales du receveur par les cellules immunitaires du donneur (effet de la greffe contre la tumeur), démontrant l'intérêt de l'analyse de la reconstitution du système immunitaire du donneur après alloHCT. De plus, le système immunitaire du donneur joue un rôle important dans la prévention et le contrôle des infections après greffe. Enfin, il est responsable de la maladie du greffon contre l'hôte (GVHD, une redoutable complication des alloHCT consistant...

618. Reconstitution du système immunitaire après allogreffe de cellules souches hématopoïétiques - Castermans, Emilie; Hannon, Muriel; Drion, Pierre; Geenen, Vincent; Beguin, Yves; Baron, Frédéric

619. Gene activation therapy: from the BLV model to HAM/TSP patients. - Lezin, Agnes; Olindo, Stephane; Belrose, Gildas; Signate, Aissatou; Cesaire, Raymond; Smadja, Didier; Macallan, Derek; Asquith, Becca; Bangham, Charles; Bouzar, Amel; Gillet, Nicolas; Defoiche, Julien; Florins, ARNAUD-FRANCOIS; Verlaeten, Olivier; Burny, Arsene; Willems, Luc
Peer reviewed

620. La Thrombinographie : vers une globalisation des tests de la coagulation. - Peters, Pierre; Gothot, André
Thrombin is the key enzyme of coagulation and thrombin generation is the central haemostatic process. Current clotting tests (PT, aPTT) measure the time at which the first fibrin filaments appear after activation of coagulation . Yet, more than 95% of thrombin is generated after clot detection, which underlies the poor sensitivity of usual clotting tests for the detection of many hemorragic or thrombotic diseases. Thrombinography measures the kinetics of thrombin generation and inactivation during ex vivo coagulation, in standardized conditions. Thrombin generation is reduced in hemophiliacs and in patients under anticoagulant treatment. Thrombin activity is raised in hypercoagulable states, such...

 

Busque un recurso